Advertisement

Economic evaluations for intensive care unit randomised clinical trials in Australia and New Zealand: Practical recommendations for researchers

Published:March 24, 2022DOI:https://doi.org/10.1016/j.aucc.2022.02.002

      Abstract

      Objectives

      Economic evaluations of intensive care unit (ICU) interventions have specific considerations, including how to cost ICU stays and accurately measure quality of life in survivors. The aim of this article was to develop best practice recommendations for economic evaluations alongside future ICU randomised controlled trials (RCTs).

      Review methods

      We collated our experience based on expert consensus across several recent economic evaluations to provide best-practice, practical recommendations for researchers conducting economic evaluations alongside RCTs in the ICU. Recommendations were structured according to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Task Force Report.

      Results

      We discuss recommendations across the components of economic evaluations, including: types of economic evaluation, the population and sample size, study perspective, comparators, time horizon, choice of health outcomes, measurement of effectiveness, measurement and valuation of quality of life, estimating resources and costs, analytical methods, and the increment cost-effectiveness ratio. We also provide future directions for research with regard to developing more robust economic evaluations for the ICU.

      Conclusion

      Economic evaluations should be built alongside ICU RCTs and should be designed a priori using appropriate follow-up and data collection to capture patient-relevant outcomes. Further work is needed to improve the quality of data available for linkage in Australia as well as developing costing methods for the ICU and appropriate quality of life measurements.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Australian Critical Care
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Iwashyna T.J.
        • Ely E.W.
        • Smith D.M.
        • Langa K.M.
        Long-term cognitive impairment and functional disability among survivors of severe sepsis.
        JAMA. 2010; 304: 1787-1794
        • Ou S.M.
        • Chu H.
        • Chao P.W.
        • Lee Y.J.
        • Kuo S.C.
        • Chen T.J.
        • et al.
        Long-term mortality and major adverse cardiovascular events in sepsis survivors. a nationwide population-based study.
        Am J Respir Crit Care Med. 2016; 194: 209-217
        • Thompson K.
        • Taylor C.
        • Jan S.
        • Li Q.
        • Hammond N.
        • Myburgh J.
        • et al.
        Health-related outcomes of critically ill patients with and without sepsis.
        Intensive Care Med. 2018;
        • Yende S.
        • Austin S.
        • Rhodes A.
        • Finfer S.
        • Opal S.
        • Thompson T.
        • et al.
        Long-term quality of life among survivors of severe sepsis: analyses of two international trials.
        Crit Care Med. 2016; 44: 1461-1467
        • Wilcox M.E.
        • Vaughan K.
        • Chong C.
        • Neumann P.J.
        • Bell C.M.
        Cost-effectiveness studies in the ICU: a systematic review.
        Crit Care Med. 2019; 47: 1011-1017
        • Australia C.o
        Council N.H.a.M.R. How to compare the costs and benefits: evaluation of the economic evidence. 2009 (Canberra)
        • Lau V.I.
        • Xie F.
        • Basmaji J.
        • Cook D.J.
        • Fowler R.
        • Kiflen M.
        • et al.
        Health-related quality-of-life and cost utility analyses in critical care: a systematic review.
        Crit Care Med. 2021; 49: 575-588
        • Ricci de Araujo T.
        • Papathanassoglou E.
        • Goncalves Menegueti M.
        • Auxiliadora-Martins M.
        • Grespan Bonacim C.A.
        • Lessa do Valle M.E.
        • et al.
        Urgent need for standardised guidelines for reporting healthcare costs in ICUs - Results of an integrative review of costing methodologies.
        Intensive Crit Care Nurs. 2019; 54: 39-45
        • Higgins A.M.
        • Peake S.L.
        • Bellomo R.
        • Cooper D.J.
        • Delaney A.
        • Howe B.D.
        • et al.
        The cost-effectiveness of early goal directed therapy: an economic evaluation alongside the ARISE trial.
        Crit Care Resusc. 2021; (In press)
        • Irving A.
        • Higgins A.
        • Ady B.
        • Bellomo R.
        • Cooper D.J.
        • French C.
        • et al.
        Fresh red cells for transfusion in critically ill adults: an economic evaluation of the standard issue Transfusion Versus Fresher Red-Cell Use in Intensive Care (TRANSFUSE) clinical trial.
        Crit Care Med. 2019; 47: e572-e579
        • Knott R.J.
        • Harris A.
        • Higgins A.
        • Nichol A.
        • French C.
        • Little L.
        • et al.
        Cost-effectiveness of erythropoietin in traumatic brain injury: a multinational trial-based economic analysis.
        J Neurotrauma. 2019; 36: 2541-2548
        • Taylor C.
        • Thompson K.
        • Finfer S.
        • Higgins A.
        • Jan S.
        • Li Q.
        • et al.
        Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST.
        Lancet Respir Med. 2016; 4: 818-825
        • Thompson K.J.
        • Young P.J.
        • Venkatesh B.
        • Cohen J.
        • Finfer S.R.
        • Grattan S.
        • et al.
        Long-term costs and cost-effectiveness of adjunctive corticosteroids for patients with septic shock in New Zealand.
        Australian Crit Care. 2021; (In Press)
        • Thompson K.J.
        • Taylor C.B.
        • Venkatesh B.
        • Cohen J.
        • Hammond N.E.
        • Jan S.
        • et al.
        The cost-effectiveness of adjunctive corticosteroids for patients with septic shock.
        Crit Care Resusc. 2020; 22: 191-199
        • Hicks P.
        • Huckson S.
        • Fenney E.
        • Leggett I.
        • Pilcher D.
        • Litton E.
        The financial cost of intensive care in Australia: a multicentre registry study.
        Med J Aust. 2019; 211: 324-325
        • Ramsey S.D.
        • Willke R.J.
        • Glick H.
        • Reed S.D.
        • Augustovski F.
        • Jonsson B.
        • et al.
        Cost-effectiveness analysis alongside clinical trials II-an ISPOR Good Research Practices Task Force report.
        Value Health. 2015; 18: 161-172
        • Husereau D.
        • Drummond M.
        • Petrou S.
        • Carswell C.
        • Moher D.
        • Greenberg D.
        • et al.
        Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
        Value Health. 2013; 16: 231-250
        • Aikawa N.
        • Fujishima S.
        • Kobayashi M.
        • Matsuoka S.
        • Abiru T.
        Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome.
        Pharmacoeconomics. 2005; 23: 169-181
        • Claxton K.
        • Posnett J.
        An economic approach to clinical trial design and research priority-setting.
        Health Econ. 1996; 5: 513-524
        • Willan A.R.
        Optimal sample size determinations from an industry perspective based on the expected value of information.
        Clin Trials. 2008; 5: 587-594
        • Willan A.R.
        • Pinto E.M.
        The value of information and optimal clinical trial design.
        Stat Med. 2005; 24: 1791-1806
        • Willan A.R.
        Sample size determination for cost-effectiveness trials.
        Pharmacoeconomics. 2011; 29: 933-949
        • Gallagher M.
        • Cass A.
        • Bellomo R.
        • Finfer S.
        • Gattas D.
        • Lee J.
        • et al.
        Long-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial.
        PLoS Med. 2014; 11e1001601
        • Williams T.A.
        • Ho K.M.
        • Dobb G.J.
        • Finn J.C.
        • Knuiman M.
        • Webb S.A.
        • et al.
        Effect of length of stay in intensive care unit on hospital and long-term mortality of critically ill adult patients.
        Br J Anaesth. 2010; 104: 459-464
        • Investigators A.
        • Group A.C.T.
        • Peake S.L.
        • Delaney A.
        • Bailey M.
        • Bellomo R.
        • et al.
        Goal-directed resuscitation for patients with early septic shock.
        N Engl J Med. 2014; 371: 1496-1506
        • Investigators N.-S.S.
        • Finfer S.
        • Chittock D.R.
        • Su S.Y.
        • Blair D.
        • Foster D.
        • et al.
        Intensive versus conventional glucose control in critically ill patients.
        N Engl J Med. 2009; 360: 1283-1297
        • Herdman M.
        • Gudex C.
        • Lloyd A.
        • Janssen M.
        • Kind P.
        • Parkin D.
        • et al.
        Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).
        Qual Life Res. 2011; 20: 1727-1736
        • Maxwell A.
        • Ozmen M.
        • Iezzi A.
        • Richardson J.
        Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data.
        Qual Life Res. 2016; 25: 3209-3219
        • Viney R.
        • Norman R.
        • King M.T.
        • Cronin P.
        • Street D.J.
        • Knox S.
        • et al.
        Time trade-off derived EQ-5D weights for Australia.
        Value Health. 2011; 14: 928-936
        • Chan K.K.
        • Willan A.R.
        • Gupta M.
        • Pullenayegum E.
        Underestimation of uncertainties in health utilities derived from mapping algorithms involving health-related quality-of-life measures: statistical explanations and potential remedies.
        Med Decis Making. 2014; 34: 863-872
        • Chuang L.H.
        • Whitehead S.J.
        Mapping for economic evaluation.
        Br Med Bull. 2012; 101: 1-15
        • Hernandez Alava M.
        • Wailoo A.
        • Wolfe F.
        • Michaud K.
        A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes.
        Med Decis Making. 2014; 34: 919-930
        • McTaggart-Cowan H.
        • Teckle P.
        • Peacock S.
        Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature.
        Expert Rev Pharmacoecon Outcomes Res. 2013; 13: 753-765
        • Health N.
        Centre for Health Record Linkage.
        2021 ([cited 2021; Available from:)
        • Independent Hospital Pricing Authority
        IHPA.
        2021 ([cited 2021; Available from:)
        • Health D.o
        Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) v5.0.
        2021 ([cited 2021; Available from:)
        • Taylor C.
        • Jan S.
        Economic evaluation of medicines.
        Aust Prescr. 2017; 40: 76-78
        • Morgan A.
        Long-term outcomes from critical care.
        Surgery (Oxf). 2021; 39: 53-57
        • Afshar M.
        • Arain E.
        • Ye C.
        • Gilbert E.
        • Xie M.
        • Lee J.
        • et al.
        Patient outcomes and cost-effectiveness of a sepsis care quality improvement program in a health system.
        Crit Care Med. 2019; 47: 1371-1379